Irisin levels in LMNA-associated partial lipodystrophies

Area of Science:

• Endocrinology
• Metabolic Disorders
• Body Composition Analysis

Background:

• Irisin, an adipo-myokine, influences energy expenditure and fat metabolism.
• Familial Partial Lipodystrophy type 2 (FPLD2) is characterized by insulin resistance, muscle hypertrophy, and lipoatrophy.
• Investigating irisin as a potential biomarker for FPLD2 is crucial for understanding its role in metabolic dysregulation.

Purpose of the Study:

• To evaluate serum irisin levels as a potential biomarker for FPLD2.
• To compare irisin and leptin levels, body composition, and metabolic parameters in FPLD2 patients, obese non-diabetic patients, and healthy controls.
• To explore the diagnostic utility of irisin and its ratio with leptin in differentiating FPLD2.

Main Methods:

• A case-control study involving 19 FPLD2 subjects, 13 obese non-diabetic patients, and 19 healthy controls.
• Measurements included serum irisin and leptin, body composition via DXA/MRI, and metabolic/inflammatory markers.
• Statistical comparisons were made between the three groups to identify significant differences.

Main Results:

• Irisin levels were elevated in both FPLD2 and obese patients compared to healthy controls.
• FPLD2 patients exhibited higher intra-abdominal to total abdominal fat ratios.
• Irisin/leptin ratios were significantly higher in FPLD2 patients compared to obese patients, suggesting diagnostic potential.

Conclusions:

• Elevated circulating irisin is observed in both FPLD2 and obese patients, linked to higher lean body mass.
• The irisin/leptin ratio shows promise as a diagnostic tool to identify FPLD2, particularly in atypical presentations.
• This ratio could facilitate earlier diagnosis and genetic testing for FPLD2.